keyword
MENU ▼
Read by QxMD icon Read
search

GnRH Antagonist

keyword
https://www.readbyqxmd.com/read/27922279/clinical-experience-with-an-ovarian-stimulation-protocol-for-intrauterine-insemination-adopting-a-gonadotropin-releasing-hormone-antagonist-at-low-dose
#1
Adalisa Ponzano, Enrica Concetta Colangelo, Lucia Di Biase, Federica Romani, Gian Mario Tiboni
Studies testing the effectiveness of GnRH antagonists in controlled ovarian stimulation (COS) for intrauterine insemination (IUI) have provided controversial results. The present study was undertaken to evaluate, whether the use of a half of the conventional dose of the GnRH antagonist cetrorelix can be effective in increasing the successful rate of IUI cycles. Patients started COS with human menopausal gonadotropin (hMG) on day three of the menstrual cycle. Cetrorelix was started when at least one follicle of ≥14 mm, was detected at the ultrasound scan, according to the flexible multiple daily dose protocol, and continued until the trigger day with recombinant hCG...
December 6, 2016: Gynecological Endocrinology
https://www.readbyqxmd.com/read/27890710/in-vivo-and-vitro-characterization-of-the-effects-of-kisspeptin-13-endogenous-ligands-for-gpr54-on-mouse-gastrointestinal-motility
#2
Jinhong Jiang, Weidong Jin, Yali Peng, Zhen He, Lijuan Wei, Shu Li, Xiaoli Wang, Min Chang, Rui Wang
Kisspeptin (KP), the endogenous ligand of GPR54, is a mammalian amidated neurohormone, which belongs to the RF-amide peptide family. However, in contrast with the related members of the RF-amide family, little information is available regarding its role in the gastrointestinal motility. With regard to the recent data suggesting KP play an important role in food intake, and while gastrointestinal motility are closely related to it. Thus, in the present work, effects of central administration of KP-13, one of the endogenous active isoforms, on gastrointestinal motility were investigated...
November 25, 2016: European Journal of Pharmacology
https://www.readbyqxmd.com/read/27872195/estrogen-receptors-and-signaling-in-fibroids-role-in-pathobiology-and-therapeutic-implications
#3
Mostafa A Borahay, Mehmet R Asoglu, Aymara Mas, Sarah Adam, Gokhan S Kilic, Ayman Al-Hendy
Uterine fibroids are the most common gynecologic tumors with a significant medical and financial burden. Several genetic, hormonal, and biological factors have been shown to contribute to the development and growth of fibroid tumors. Of these factors, estrogen is particularly critical since fibroids are considered estrogen dependent because no prepubertal cases have been described in the literature and tumors tend to regress after menopause. Understanding the role of estrogen in fibroids is not only important for understanding the pathobiology of fibroids but also for the development of successful therapeutics...
November 20, 2016: Reproductive Sciences
https://www.readbyqxmd.com/read/27836979/a-mild-ovarian-stimulation-strategy-in-women-with-poor-ovarian-reserve-undergoing-ivf-a-multicenter-randomized-non-inferiority-trial
#4
M A Youssef, M van Wely, H Al-Inany, T Madani, N Jahangiri, S Khodabakhshi, M Alhalabi, M Akhondi, S Ansaripour, R Tokhmechy, L Zarandi, A Rizk, M El-Mohamedy, E Shaeer, M Khattab, M H Mochtar, F van der Veen
STUDY QUESTION: In subfertile women with poor ovarian reserve undergoing IVF does a mild ovarian stimulation strategy lead to comparable ongoing pregnancy rates in comparison to a conventional ovarian stimulation strategy? SUMMARY ANSWER: A mild ovarian stimulation strategy in women with poor ovarian reserve undergoing IVF leads to similar ongoing pregnancy rates as a conventional ovarian stimulation strategy. WHAT IS KNOWN ALREADY: Women diagnosed with poor ovarian reserve are treated with a conventional ovarian stimulation strategy consisting of high-dose gonadotropins and pituitary downregulation with a long mid-luteal start GnRH-agonist protocol...
November 11, 2016: Human Reproduction
https://www.readbyqxmd.com/read/27831635/short-gonadotropin-releasing-hormone-agonist-versus-flexible-antagonist-versus-clomiphene-citrate-regimens-in-poor-responders-undergoing-in-vitro-fertilization-a-randomized-controlled-trial
#5
M Schimberni, F Ciardo, M Schimberni, A Giallonardo, V De Pratti, M Sbracia
OBJECTIVE: Poor responders represent a frustrating condition for couples undergoing IVF and clinicians, and their treatment remains disputed. To assess the efficacy and the most suitable protocol, we conducted a randomized controlled trial comparing three different protocols of ovarian stimulation in poor responder women: clomiphene citrate (CC) plus a high dose of gonadotropins and GnRH antagonist, flexible GnRH antagonist protocol and a short GnRH agonist protocol. PATIENTS AND METHODS: Between July 2014 and December 2015 we enrolled 250 poor responders in a previous IVF cycle at least 3 months before...
October 2016: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/27817036/freeze-all-cycle-for-all-normal-responders
#6
Matheus Roque, Marcello Valle, Fernando Guimarães, Marcos Sampaio, Selmo Geber
PURPOSE: The purpose of this study is to evaluate the freeze-all strategy in subgroups of normal responders, to assess whether this strategy is beneficial regardless of ovarian response, and to evaluate the possibility of implementing an individualized embryo transfer (iET) based on ovarian response. METHODS: This was an observational, cohort study performed in a private IVF center. A total of 938 IVF cycles were included in this study. The patients were submitted to controlled ovarian stimulation (COS) with a gonadotropin-releasing hormone (GnRH) antagonist protocol and a cleavage-stage day 3 embryo transfer...
November 5, 2016: Journal of Assisted Reproduction and Genetics
https://www.readbyqxmd.com/read/27816925/a-short-course-of-metformin-does-not-reduce-ohss-in-a-gnrh-antagonist-cycle-for-women-with-pcos-undergoing-ivf-a-randomised-placebo-controlled-trial
#7
S L Jacob, C Brewer, T Tang, H M Picton, J H Barth, A H Balen
STUDY QUESTION: Does 'metformin' reduce the incidence of ovarian hyperstimulation syndrome (OHSS) for women with polycystic ovary syndrome (PCOS) undergoing a GnRH antagonist assisted conception treatment cycle? SUMMARY ANSWER: A short course of metformin does not reduce the incidence of OHSS for women with PCOS undergoing a GnRH antagonist treatment cycle. WHAT IS KNOWN ALREADY: Metformin does reduce the incidence of OHSS in a GnRH-agonist treatment cycle...
November 5, 2016: Human Reproduction
https://www.readbyqxmd.com/read/27815485/estradiol-pretreatment-in-an-ultrashort-gnrh-combined-with-a-gnrh-antagonist-protocol-in-a-cohort-of-poor-responders-undergoing-ivf-icsi-a-case-control-study
#8
Charalampos Siristatidis, George Salamalekis, Paraskevi Vogiatzi, Tereza Vrantza, Paraskevi Matsota, Vasileios Pergialiotis, Nikolaos Papantoniou
AIM: To provide results of the use of estradiol pretreatment in a combination of an ultrashort gonadotropin-releasing hormone (GnRH) agonist and antagonist protocol, in an attempt to improve the clinical outcomes in "poor responders", according to the Bologna criteria, undergoing in vitro fertilization (IVF). PATIENTS AND METHODS: We applied estradiol pretreatment to 20 participants before the initiation of a combination of an ultrashort GnRH agonist plus an GnRH antagonist protocol followed by high doses of gonadotropins; the control group consisted of 20 subfertile participants with matching age, body mass index (BMI), basal follicle-stimulating hormone (FSH) and anti-Müllerian hormone (AMH), antral follicle count (AFC) and cause of subfertility, conforming with the same inclusion criteria and treated with a fixed GnRH antagonist protocol...
November 2016: In Vivo
https://www.readbyqxmd.com/read/27808664/dynamics-of-the-development-of-multiple-follicles-by-early-versus-late-hcg-administration-in-art-program
#9
Maddalena Falagario, Paolo Trerotoli, Annarosa Chincoli, Isabella Cobuzzi, Margherita P Vacca, Doriana Falagario, Claudia Nardelli, Raffaella Depalo
OBJECTIVE: To evaluate, in patients stimulated with recombinant FSH and GnRH antagonists, whether triggering the final maturation of oocytes affects IVF outcomes. STUDY DESIGN: Five hundred and six IVF procedures were divided into three groups according to the timing of hCG administration: when at least 2 follicles reached the diameter of 17 mm, at least 2 follicles reached 18 mm and at least 2 follicles reached 20 mm. The main outcome was the number of mature oocyte that was the dependent variable of a multivariate model whose independents were, age, AFC, hCG timing, E2 levels at hCG day, number of follicles in different categories of dimension...
November 3, 2016: Gynecological Endocrinology
https://www.readbyqxmd.com/read/27803584/gonadotropin-releasing-hormone-agonist-trigger-is-a-better-alternative-than-human-chorionic-gonadotropin-in-pcos-undergoing-ivf-cycles-for-an-ohss-free-clinic-a-randomized-control-trial
#10
Deepika Krishna, Snehal Dhoble, Gautham Praneesh, Suvarna Rathore, Amit Upadhaya, Kamini Rao
OBJECTIVE: The objective of this study is to evaluate if gonadotropin-releasing hormone agonist (GnRHa) trigger is a better alternative to human chorionic gonadotropin (hCG) in polycystic ovary syndrome (PCOS) of Indian origin undergoing in vitro fertilization (IVF) cycles with GnRH antagonist for the prevention of ovarian hyperstimulation syndrome (OHSS). DESIGN: Prospective randomized control trial. SETTING: Tertiary care center. MATERIALS AND METHODS: A total of 227 patients diagnosed with PCOS, undergoing IVF in an antagonist protocol were recruited and randomly assigned into two groups: Group A (study group): GnRHa trigger 0...
July 2016: Journal of Human Reproductive Sciences
https://www.readbyqxmd.com/read/27803582/impact-of-gonadotropin-releasing-hormone-antagonist-addition-on-pregnancy-rates-in-gonadotropin-stimulated-intrauterine-insemination-cycles
#11
Shikha Jain, Abha Majumdar
OBJECTIVES: The objective of the study is to evaluate the efficacy of gonadotropin-releasing hormone (GnRH) antagonist in improving clinical pregnancy rate in gonadotropin-stimulated intrauterine insemination (IUI) cycles in patients of unexplained infertility. STUDY DESIGN: This was a prospective, randomized case-controlled study. SETTINGS: The study was conducted in the infertility clinic of a tertiary care center. MATERIALS AND METHODS: Four hundred twenty-seven women undergoing IUI following controlled ovarian stimulation with gonadotropins (recombinant follicle-stimulating hormone [r-FSH] 75 IU/day) were randomly divided into two groups...
July 2016: Journal of Human Reproductive Sciences
https://www.readbyqxmd.com/read/27793455/effects-of-long-acting-gnrh-antagonist-degarelix-acetate-on-plasma-insulin-like-peptide-3-testosterone-and-luteinizing-hormone-concentrations-and-scrotal-circumference-in-male-goats
#12
M A Hannan, N Kawate, Y Fukami, W W P N Weerakoon, E E Büllesbach, T Inaba, H Tamada
We recently reported that plasma insulin-like peptide 3 (INSL3) concentrations increased soon after endogenous and exogenous stimulations of LH in male goats and bulls. However, the effects of LH suppression on INSL3 secretion are unknown in domestic animals. Here, we examined the effects of a long-acting GnRH antagonist (degarelix acetate; 4 mg/kg) on the secretions of plasma INSL3 and testosterone in two phases, an immediate and a long-term phase in male goats (n = 6; aged, 13-16 months). During the immediate phase, blood was taken at 15-minute intervals for 8 hours on Days -5, 0, and 3...
January 15, 2017: Theriogenology
https://www.readbyqxmd.com/read/27793383/steroid-hormone-pretreatments-in-assisted-reproductive-technology
#13
REVIEW
Jean Nassar, Teddy Tadros, Elodie Adda-Herzog, Jean Marc Ayoubi, Renato Fanchin
Adequate availability and FSH sensitivity of ovarian antral follicles and coordination of their growth during controlled ovarian hyperstimulation (COH) rank among factors that may determine outcome, particularly in patients presenting ovarian function defects and so-called "poor responders." Growing evidence indicates that both factors are positively influenced by steroid hormone pretreatments. First, data from studies conducted in both animals and in women exposed to virilizing androgen doses indicate that androgen pretreatments may increase follicle responsiveness to FSH and/or the number of growing follicles in the ovary, thereby constituting an interesting perspective in the management of "poor responders...
December 2016: Fertility and Sterility
https://www.readbyqxmd.com/read/27792406/developmental-programming-insulin-sensitizer-prevents-the-gnrh-stimulated-lh-hypersecretion-in-a-sheep-model-of-pcos
#14
Rodolfo C Cardoso, Ashleigh Burns, Jacob Moeller, Donal C Skinner, Vasantha Padmanabhan
Prenatal testosterone (T) treatment recapitulates the reproductive and metabolic phenotypes of polycystic ovary syndrome in female sheep. At the neuroendocrine level, prenatal T treatment results in disrupted steroid feedback on gonadotropin release, increased pituitary sensitivity to GnRH, and subsequent LH hypersecretion. Because prenatal T-treated sheep manifest functional hyperandrogenism and hyperinsulinemia, gonadal steroids and/or insulin may play a role in programming and/or maintaining these neuroendocrine defects...
December 2016: Endocrinology
https://www.readbyqxmd.com/read/27771155/final-oocyte-maturation-with-two-different-gnrh-agonists-in-antagonist-co-treated-cycles-at-risk-of-ovarian-hyperstimulation-syndrome
#15
Yavuz Emre Şükür, Batuhan Özmen, Elif Didem Özdemir, Mehmet Murat Seval, Erkan Kalafat, Murat Sönmezer, Bülent Berker, Ruşen Aytaç, Cem Somer Atabekoğlu
Triptorelin 0.2 mg and leuprolide 1 mg subcutaneous injections for triggering final follicular maturation were compared in patients with a high risk for ovarian hyperstimulation syndrome (OHSS). Infertile patients treated with GnRH antagonist protocol between January 2014 and March 2016 were recruited. Patients with high serum oestradiol levels on HCG day (>3000 pg/ml) indicating a risk of OHSS consisted of the study groups (A and B). Patients with serum oestradiol levels less than 3000 pg/ml consisted of the control group (C)...
October 17, 2016: Reproductive Biomedicine Online
https://www.readbyqxmd.com/read/27768220/gnrh-agonist-or-antagonist-in-the-treatment-of-prostate-cancer-a-comparision-based-on-oncological-results
#16
Stefano Salciccia, Alessandro Gentilucci, Susanna Cattarino, Alessandro Sciarra
On the basis of the trials available, are we ready to consider GnRH antagonists better than agonists? Is there a population of patients who may benefit from antagonists more than agonists?We specifically focused our analysis on the significance of oncological results obtained in phase III trials directly comparing Degarelix with GnRH agonists. Oncological results were evaluated only in 1 trial (CS21) with some subanalysis and they were not the primary endpoints of the study. The follow-up duration was 364 days, and therefore, the number of events (all causes deaths and prostate cancer (PC), Prostate Specific Antigen (PSA), Hazard ratio (HR)-related deaths) was very low in both groups and this aspect strongly reduces the significance of overall survival evaluation...
November 18, 2016: Urologia
https://www.readbyqxmd.com/read/27756786/a-phase-ii-randomized-open-label-study-of-neoadjuvant-degarelix-versus-lhrh-agonist-in-prostate-cancer-patients-prior-to-radical-prostatectomy
#17
Rashid Sayyid, Andrew Evans, Karen Hersey, Ranjena Maloni, Antonio Hurtado-Coll, Girish Kulkarni, Antonio Finelli, Alexandre R Zlotta, Robert Hamilton, Martin Gleave, Neil Fleshner
PURPOSE: Degarelix, a new GnRH receptor antagonist with demonstrated efficacy as first-line treatment in the management of high-risk prostate cancer, possesses some theoretical advantages over LHRH analogues in terms of avoiding "testosterone flare" and lower FSH levels. We set out to determine if pre-operative degarelix influenced surrogates of disease control in a randomized phase II study. EXPERIMENTAL DESIGN: 39 patients were randomly assigned to one of 3 different neo-adjuvant arms: degarelix only, degarelix/bicalutmaide, or LHRH agonist/bicalutamide...
October 18, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27738657/gnrh-agonist-trigger-versus-hcg-trigger-in-gnrh-antagonist-in-ivf-icsi-cycles-a-review-article
#18
REVIEW
Ashraf Alyasin, Shayesteh Mehdinejadiani, Marzieh Ghasemi
Routinely, a bolus of 5.000-10.000 IU human chorionic gonadotropin (hCG) is used for the final follicular maturation and ovulation as a standard method. HCG has the same effect of luteinizing hormone (LH) with long half-life. It has the long lutheotrophic effect which increases the risk of ovarian hyper stimulation syndrome (OHSS). Recently, gonadotropin-releasing hormone agonist (GnRH-a) trigger has been used for the induction of final follicular maturation and ovulation with the aim of reducing the OHSS risk...
September 2016: International Journal of Reproductive Biomedicine (Yazd, Iran)
https://www.readbyqxmd.com/read/27732089/serotonin-receptor-1a-htr1a-a-novel-regulator-of-gnrh-neuronal-migration-in-chick-embryo
#19
Subathra Poopalasundaram, David Chambers, Anthony Graham, Pierre-Marc Bouloux
The hypothalamic GnRH neurons are a small group of cells that regulate the reproductive axis. These neurons are specified within the olfactory placode, delaminate from this structure, and then migrate to enter the forebrain before populating the hypothalamus. We have used microarray technology to analyze the transcriptome of the olfactory placode at a number of key time points for GnRH ontogeny using the chick embryo. This resulted in the identification of a large number of genes whose expression levels change significantly over this period...
December 2016: Endocrinology
https://www.readbyqxmd.com/read/27729967/corifollitropin-stimulation-in-combination-with-gnrh-antagonists-after-estradiol-valerate-pre-treatment-a-pilot-study-on-patientfriendly-ivf
#20
W Decleer, K Verschueren, S Vandeginste, K Osmanagaoglu, P Devroey
OBJECTIVE: To demonstrate the feasibility of scheduling an IVF cycle, without disadvantages, in the new patient friendly stimulation protocol using the long acting Corifollitropin Alfa, in combination with GnRH-antagonist protection and GnRH-agonist triggering. STUDY DESIGN: Two groups of ten patients were admitted in the study. Both received the same stimulation protocol with Corifollitropin Alfa in combination with GnRH-antagonist protection. After ultrasound evaluation on day 7 individually dosed Menopur was added...
December 28, 2015: Facts, Views & Vision in ObGyn
keyword
keyword
22470
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"